When the BCR::ABL1 international score (IS) meets response milestones at 3, 6, and 12 months (≤ 10% BCR::ABL1 IS at 3 and, ≤ 1% BCR::ABL1 IS at 6 months and ≤ 0.1% BCR::ABL1 IS at ≥12 months) post therapy, these patients are classified as TKI responders, and others as inadequate responders (Figure 3B).(61) We then performed qPCR in normal and CML patient cells for LN989, PROX1-AS1, SENCR, LN892 and KIF25-AS1, which are consistently elevated in resistant K562 cells. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.